Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $51 million or $0.97 per share, compared to a net loss of $36.7 million or $0.85 per share for Q4 2024 [22] - The net loss for the full year 2025 was $177 million or $3.79 per share, compared to $111.8 million or $2.83 per share for 2024 [23] - Non-GAAP adjusted net loss for Q4 2025 was $38.4 million or $0.73 per share, compared to $32.3 million or $0.75 per share for Q4 2024 [24] - Non-GAAP adjusted net loss for the full year 2025 was $150.8 million or $3.22 per share, compared to $101.9 million or $2.58 per share for 2024 [24] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses for Q4 2025 were $37.6 million, up from $33.5 million in the prior year [25] - R&D expenses for the full year 2025 were $145 million, compared to $104.2 million for the prior year [25] - General and administrative (G&A) expenses for Q4 2025 were $11.6 million, compared to $3 million for the prior year [26] - G&A expenses for the full year 2025 were $27.2 million, compared to $9.1 million for the prior year [26] Market Data and Key Metrics Changes - The total addressable market for gedatolisib in the second-line setting is estimated to be more than $5 billion, with potential peak revenue of up to $2.5 billion annually [17] Company Strategy and Development Direction - The company aims to establish gedatolisib as a new standard of care therapy for HR-positive, HER2-negative advanced breast cancer, with a PDUFA goal date of July 17, 2026 [4] - The company is preparing for the potential launch of gedatolisib, having built a sales force and internal systems required for commercial operations [15] - The company is engaging with payers and strategic accounts to ensure access to gedatolisib for oncologists and their patients [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the FDA's review of the NDA for gedatolisib, citing unprecedented efficacy data from clinical trials [5] - The company believes that the positive results from the PIK3CA wild-type cohort of the VIKTORIA-1 study will support the efficacy of gedatolisib in the second-line setting [12] - Management highlighted the importance of the safety profile of gedatolisib, which does not induce significant glycemic disruption, making it suitable for a broader patient population [68] Other Important Information - Cash, cash equivalents, and short-term investments were $441.5 million at the end of fiscal year 2025, expected to finance operations through 2027 [28] Q&A Session Summary Question: Status of mutant data database lock - Management could not comment on the database lock status [31] Question: Details on the mutant data disclosure - Management indicated that top-line data will be provided in a press release, with details at a medical conference [32] Question: Feedback from physicians on launch segments - Management stated that the sales force will reach out to doctors generally to explain how gedatolisib offers improvements over current alternatives [40] Question: Will physicians use gedatolisib off-label for mutants? - Management confirmed that there have been no discussions with doctors about off-label use [41] Question: Details on the top-line release of median data - Management confirmed that the top-line release will include a statement regarding the achievement of statistical significance [46] Question: Key gating factor for frontline endocrine-sensitive trial - The key gating factor is completing the safety run-in for the trial [56] Question: Challenges in getting patients for infusions - Management believes that efficacy is the most important factor for physicians and that patient pushback on IV administration will be minimal [58] Question: Thoughts on competition from next-generation assets - Management believes that comprehensive inhibition of the PI3K pathway is necessary for optimal antitumor control, and they see limited biological potential in single-target inhibitors [90]

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [21] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [21][22] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [22][23] - Commercial expenses surged to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [23] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024, with a full-year net loss of $63.1 million or $0.75 per share compared to $41.5 million or $0.67 per share in 2024 [24] Business Line Data and Key Metrics Changes - The launch of CARDAMYST, an etripamil nasal spray for PSVT, marks a significant new therapeutic option for over 2 million patients, with the commercial strategy focused on driving new patient starts and achieving commercial coverage [5][7] - The commercial team has engaged with approximately 10,000 providers who manage half of the 1 million patients expected to receive treatment for PSVT in 2026 [12] Market Data and Key Metrics Changes - The PSVT market is identified as a clearly defined opportunity within cardiovascular specialty pharma, with efforts to demonstrate the value proposition of CARDAMYST to payers [13] - Initial feedback from prescribers has been positive, with over 150 prescriptions filled in the first month of launch, primarily from new patient starts [16] Company Strategy and Development Direction - The FDA approval of CARDAMYST is seen as a foundation for value creation, with plans to leverage clinical data for marketing approvals in other regions, including Europe [8][9] - The company aims to establish a strong commercial franchise and reduce reliance on emergency department care through the self-administered CARDAMYST [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch phase, noting that while it is too early to identify durable patterns, they expect prescription volume to increase and commercial coverage to expand over time [20] - The company is focused on ensuring that physicians can prescribe CARDAMYST, patients can access it, and payers recognize the demand in the marketplace [20] Other Important Information - The company reported a pro forma cash figure of approximately $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [10][24] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [10] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted broad adoption among cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [28][31] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks after engaging the system, with ongoing efforts to support patients during the reimbursement process [35][38] Question: Replacement therapies for CARDAMYST and patient feedback - Management reported a broad range of patients using CARDAMYST, including those awaiting ablation, with positive early feedback from social media indicating excitement about having the treatment available [46][49] Question: Contracting strategy and formulary positioning - Management aims for open access with reasonable coverage terms, expecting a 50/50 split between commercial and Medicare patients, and is actively engaging payers for coverage [58][61]

Core Insights - The company achieved significant revenue growth in 2025, driven by the launch of Sephience, a drug for PKU, generating over $111 million in revenue within the first 5.5 months [1] - The company ended 2025 with approximately $1.95 billion in cash, positioning itself well for future commercial and R&D initiatives [2] - Continued strong momentum is expected in the U.S. market, with revenue growth anticipated to be driven by Sephience throughout the year [3]

Vertex Pharmaceuticals Conference Call Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Date**: March 10, 2026 - **Key Focus**: Discussion on company goals, product pipeline, and financial outlook Core Industry Insights 1. Company Goals for 2026 - Extend leadership in Cystic Fibrosis (CF) - Accelerate commercial diversification, particularly with DRNAvx and CASGEVY - Advance a broad pipeline with five ongoing Phase 3 trials - Deliver consistent financial results with revenue guidance of **$12.95 billion to $13.1 billion**, indicating **8%-9% growth** [7][8] 2. Product Pipeline and Efficacy Data - **POVI (povotazacet)**: - Recent data showed a **52% reduction in UPCR** at 36 weeks compared to baseline and a **50% reduction relative to placebo** [9] - Secondary endpoints showed a **77% reduction in Gd-IgA1 antibodies** and an **85% resolution rate in hematuria** [9] - Safety profile was strong with no serious adverse events (SAEs) related to POVI and no deaths in the trial [10] - Filing for regulatory approval expected by the end of March 2026 [11] 3. Commercialization Strategy - POVI is positioned as a potential best-in-class product due to its efficacy, safety, and convenient dosing [30] - The company is gearing up for a launch, having started planning in mid-2025 [31] 4. Growth Prospects - Continued growth in CF expected, with ongoing launches of ALYFTREK in the U.S. and internationally [22] - Anticipated tripling of JOURNAVX prescriptions in 2026, with coverage for approximately **200 million lives** [23][58] - Non-CF products like CASGEVY and JOURNAVX expected to become multibillion-dollar businesses [24][25] 5. Financial Outlook - Operating margins maintained in the low-to-mid **40% range** despite ongoing investments in the pipeline [24] - Investments in five Phase 3 trials and commercial organization for new products are expected to drive growth [24] Additional Important Insights 1. Competitive Landscape - Comparison with competitors like ATSUCA, noting that their data is at a later time point (week 40) [13] - Emphasis on the real-world population in the study, with a significant time from diagnosis to enrollment [19] 2. Future Data Releases - Additional data from ongoing trials will be released at appropriate times, with a focus on maintaining transparency with stakeholders [12] 3. Patient Support Programs - Medicare patients currently have access to JOURNAVX through a patient support program until formal coverage is secured [61][64] 4. Upcoming Milestones - Phase 3 results for DPN expected in late 2026 or early 2027 [26] - VX-828 Phase 1b data anticipated in the second half of 2026 [70][74] 5. CASGEVY Progress - Positive progress noted with over **300 patients** starting treatment in 2025, with expectations for continued growth in 2026 [76] This summary encapsulates the key points discussed during the Vertex Pharmaceuticals conference call, highlighting the company's strategic goals, product pipeline advancements, and financial outlook.

Financial Data and Key Metrics Changes - In 2025, LINZESS U.S. net sales reached $865 million, with an 11% demand growth and 8% new-to-brand volume growth year-over-year [5][6] - The company reported a total revenue of $296 million for 2025, with GAAP net income of $24 million and Adjusted EBITDA of $138 million [19][21] - The company ended 2025 with $250 million in cash and cash equivalents, positioning itself well for 2026 [7][22] Business Line Data and Key Metrics Changes - LINZESS maintained its prescription market leadership for IBS-C and chronic constipation, achieving approximately 45% market share and surpassing 5.7 million unique patients treated since launch [11][12] - In Q4 2025, LINZESS U.S. net sales decreased by 27% year-over-year, primarily due to net price erosion, despite a 13% prescription demand growth [19][20] - The company expects LINZESS to return to blockbuster status in 2026, projecting U.S. net sales of over $1.1 billion, driven by improved net pricing and low single-digit prescription demand growth [7][23] Market Data and Key Metrics Changes - The company anticipates a more than 30% increase in LINZESS U.S. net sales in 2026 due to the elimination of the inflationary component of statutory required rebates [13][14] - The market for LINZESS remains strong, with over 40 million addressable patients in the U.S. and significant unmet needs in the IBS-C treatment space [11][12] Company Strategy and Development Direction - The company aims to maximize LINZESS and advance apraglutide, with clear priorities for 2026 including disciplined expense management and debt reduction [8][23] - The company plans to initiate the STARS-2 confirmatory Phase III trial for apraglutide in Q2 2026, with expectations of supporting an NDA submission by the end of 2029 [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial opportunity for apraglutide, citing strong efficacy and tolerability data, and the potential to redefine the standard of care for short bowel syndrome [9][10] - The company is optimistic about the future of LINZESS, expecting continued strong net sales and cash flows, despite not providing specific guidance for 2027 and beyond [41] Other Important Information - The company has taken steps to lower the LINZESS list price effective January 1, 2026, to enhance patient access amid evolving healthcare dynamics [6][12] - The company is focused on maximizing shareholder value while considering strategic alternatives, given its improved financial position [34] Q&A Session Summary Question: Details on STARS-2 trial learnings and enrollment timeline - Management highlighted improvements in dosing administration and confidence in repeating the data from STARS-1, with a robust enrollment strategy for STARS-2 [27][30] Question: Update on strategic alternatives process - Management noted a significantly improved financial position and a clear path forward, while remaining open to alternatives that could enhance shareholder value [34] Question: Market opportunity for apraglutide amid potential generics - Management expressed strong conviction in apraglutide's clinical profile and market potential, even with anticipated competition from generics [56]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% year-over-year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [17] - Cash and cash equivalents at year-end were $323 million, compared to $315 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [5][20] - Sunosi posted Q4 net product revenue of $36.7 million, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13][25] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [14] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [20] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [21] - Symbravo's payer coverage is approximately 52% at the start of the year, with ongoing negotiations expected to expand this coverage [24] Company Strategy and Development Direction - The company is focused on scaling growth across its commercial organization and expanding adoption of CNS medicines [25] - A significant expansion of the Auvelity sales force to approximately 600 representatives is planned to support growth in MDD and potential Alzheimer's disease agitation [22][64] - The company is advancing a broad CNS pipeline, including five novel product candidates across nine high-impact indications [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of Auvelity in addressing Alzheimer's disease agitation, with launch readiness activities underway [7][74] - The company anticipates continued momentum in its commercial business and expects to achieve cash flow positivity based on its current operating plan [18] - Management highlighted the importance of ongoing negotiations with payers to ensure access for both MDD and ADA indications [56] Other Important Information - The company has made significant progress in its CNS pipeline, including planned trials for AXS-05 in smoking cessation and AXS-12 in narcolepsy [8][9] - The company acquired AZD7325, a novel oral GABA A receptor modulator, to evaluate for the treatment of epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [29][30] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for phase II readiness [35][36] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but additional efforts are being made for Medicare coverage [40][41] Question: Drivers of Sunosi's growth - Growth is driven by both OSA and narcolepsy markets, with positive trends in new patient starts and prescriber behavior [48] Question: Progress of the DTC campaign for Auvelity - The national TV campaign has generated an inflection in new patient starts, with growth seen in primary care and psychiatry [52][53] Question: Expected reimbursement and market access for Auvelity - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives [56] Question: Coverage evolution for Symbravo - Secured contracts with large GPOs will facilitate negotiations with payers, with optimism about increasing coverage [68][70] Question: Launch readiness for Alzheimer's disease agitation - The company will be ready to launch within a quarter post-approval, with plans to share metrics on script percentages from the ADA space [74]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses at $77.5 million and G&A at $19.5 million [17] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024 [17] - The cash position at the end of Q4 2025 was $926 million, significantly increased from $469 million at the end of 2024, primarily due to proceeds from a follow-on public offering [18] Business Line Data and Key Metrics Changes - Ulixacaltamide showed positive results in the Essential3 program, with significant improvements in key endpoints, leading to a breakthrough designation from the FDA [8][9] - Relutrigine demonstrated strong efficacy in the EMBOLD study for SCN2A and SCN8A DEEs, with a potential annual revenue of $5 billion [12] - Vormatrigine achieved a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with expectations for multiple readouts in the next 12-18 months [13][14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, with a peak potential revenue of over $10 billion annually [9][10] - The initial addressable population for relutrigine is approximately 10,000 patients in the U.S., with a broader potential of over 200,000 patients with DEE [12] - Vormatrigine targets approximately 3 million people in the U.S. suffering from common epilepsies, with potential annual revenue exceeding $4 billion [14] Company Strategy and Development Direction - The company aims to transform into a commercial entity with two NDA submissions for ulixacaltamide and relutrigine, focusing on enhancing its clinical portfolio [6][16] - Preparations for the commercial launch of ulixacaltamide include building a commercial organization and a comprehensive medical education campaign [10][22] - The company is strategically focused on the U.S. market while acknowledging the unmet need for treatments outside the U.S. [86] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting a strong balance sheet and the potential for significant revenue opportunities across its CNS portfolio [17][19] - The company is positioned for a catalyst-rich year with multiple readouts from its innovative pipeline and plans for an R&D day to discuss clinical programs [16] - Management emphasized the importance of understanding the disease and clinical data for prescribers as part of their pre-commercial activities [24][25] Other Important Information - The company has initiated pre-launch activities for both ulixacaltamide and relutrigine, including key hires and inventory building [22][31] - The EMBRAVE3 trial for elsunersen has been updated to a single-arm, baseline-controlled study, with expectations for completion later this year [15][81] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness and prescriber education [22] Question: What additional data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for Relyxa? - The FDA did not require additional studies for alternative titration schedules, and the company is focused on ensuring the drug's tolerability [29][30] Question: How will the POWER3 study help move towards the front line setting? - The study aims to address the needs of a broader patient population with focal seizures, focusing on those who are not well managed with current treatments [40][41] Question: Why did you not request priority review for ulixacaltamide? - The decision was based on strategic considerations regarding launch timing and maximizing long-term revenue potential [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present multiple follow-up data points to reinforce the drug's value [51] Question: What is the expected utility of relutrigine across the DEE spectrum? - The company anticipates that relutrigine will serve as a foundational therapy for a diverse group of DEE patients [68][69]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% year-over-year [5][30] - Net sales in Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [6][30] - GAAP R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [30] - GAAP SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% year-over-year [30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase versus 2024, with significant contributions from Opzelura, Niktimvo, and Monjuvi [6][10] - Jakafi sales in Q4 were $828 million, a 7% increase year-over-year, with full-year sales at $3.093 billion, an 11% increase [7] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10] Market Data and Key Metrics Changes - The U.S. market for Opzelura in atopic dermatitis (AD) is growing at nearly 20% year-over-year, while the vitiligo market is growing in the mid-teens [46] - The pediatric launch of Opzelura AD is annualizing around $30 million, indicating strong market uptake [9][46] - The international sales for Opzelura in vitiligo doubled to $130 million in 2025, with expectations for continued growth [9] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development, targeting MPNs, pancreatic cancer, colorectal cancer, and hidradenitis suppurativa (HS) [4][5] - The company anticipates significant growth in its core business, potentially matching Jakafi's current size by 2030, driven by upcoming product launches [13] - The company is focused on expanding its hematology portfolio and advancing novel therapies in myeloproliferative neoplasms [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a strong foundation for an inflection point in 2026 and beyond [5] - The company expects total revenues for 2026 to be between $4.77 billion and $4.94 billion, representing a 10%-13% increase from the prior year [32] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [35] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura for moderate AD, and povorcitinib for HS in Europe [5] - The company plans to initiate 14 pivotal trials across seven assets by the end of 2026, reflecting a robust pipeline [14][17] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management is discussing dosing strategies with the FDA to address differential potency across CALR mutations and is confident in their approach [39][40] Question: Opzelura uptake and average usage - The AD business is growing at nearly 20% year-over-year, with significant contributions from the pediatric launch and international markets [46][47] Question: Monjuvi's opportunity in front-line DLBCL - Monjuvi is positioned as an addition to R-CHOP, with a focus on a broad patient population, and management is optimistic about its competitive edge [54][55] Question: Opzelura in PN and FDA recommendations - The FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, but there is no read-through to HS [62][66] Question: Updates on mCALR bispecific and V617F programs - The mCALR bispecific program is accelerating, and management is optimistic about the V617F program's potential to address a significant patient population [72][75]

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [4][29] - Net sales for Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [5][29] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [29][30] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% [29][30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase from 2024, with expectations for over 30% growth in 2026 [5][12] - Jakafi sales in Q4 were $828 million, an increase of 7% year-over-year, with full-year sales at $3.093 billion, representing an 11% increase [6][29] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9][29] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10][29] Market Data and Key Metrics Changes - The pediatric launch of Opzelura for atopic dermatitis is performing well, with annualized sales around $30 million [9] - International sales for Opzelura in vitiligo doubled to $130 million in 2025 [9] - The hematology and oncology business is expected to generate $800-$880 million in 2026, representing a 40%-50% increase compared to 2025 [12][29] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development [3][4] - The focus is on expanding the core business, with expectations for product launches in late 2026 and early 2027 [12][14] - The company views business development as a multiplier to strengthen its core, with a focus on strategic fit and potential for durable revenue [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with a revenue guidance for 2026 set at $4.77 billion-$4.94 billion, a 10%-13% increase from the prior year [31][32] - The company anticipates a significant increase in core business growth, with expectations for Jakafi sales to be between $3.22 billion and $3.27 billion in 2026 [31] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [32] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura, and povorcitinib in Europe [4] - The pipeline has reached a new level of maturity, with 14 pivotal trials expected to be underway by the end of 2026 [15][16] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management indicated that they will discuss dosing strategies with the FDA and are confident in their approach [36][39] Question: Opzelura uptake and average usage - Management noted that the AD business is growing at nearly 20% year-over-year, with significant growth expected in the pediatric segment [42][45] Question: Monjuvi's opportunity in front-line DLBCL - Management highlighted that Monjuvi is positioned as an addition to R-CHOP, with a competitive PFS benefit [47][51] Question: Opzelura in PN and FDA recommendations - Management clarified that the FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, with no implications for HS [59][62] Question: mCALR bispecific and V617F program - Management expressed confidence in the mCALR bispecific program and the potential of the V617F program to deliver transformative clinical effects [64][68]

Core Insights - TG Therapeutics is focused on developing treatments for B-cell diseases, with its flagship product BRIUMVI targeting relapsing multiple sclerosis (RMS) [1] Financial Performance - Goldman Sachs updated its rating for TG Therapeutics to Neutral, maintaining a hold recommendation, with the stock price at $29.54 and a raised price target from $37 to $39 [2][6] - TG Therapeutics projects FY25 revenue to reach approximately $616 million, an 87% increase from $329 million in FY24, and anticipates FY26 revenue between $875 million and $900 million [3][6] - BRIUMVI is expected to contribute around $594 million in product revenue for FY25, with FY26 projections ranging from $825 million to $850 million [4][6] Market Position - Despite a 7.7% decline in shares over the past year, TG Therapeutics remains optimistic about long-term revenue growth driven by BRIUMVI's commercial performance and market share capture [5]